ESPE Abstracts

Background: While research demonstrated successful weight and BMI reduction in response to recent obesity drugs in adults and adolescents, there are significant limitations of current drugs targeting single receptors, such as problems maintaining a reduced weight status, and the high rates of gastrointestinal adverse events, which can lead to discontinuation of treatment. Based on this, we hypothesized that a more effective and better tolerated obesity interve...

Designing monomeric dual or triple agonists based on glucagon-like peptide (GLP)-1 with glucagon, and/or glucose-dependent insulinotropic polypeptide (GIP) are promising novel approaches for anti-obesity drugs tackling different weight-regulatory pathways, albeit such developments continue to suffer from significant gastrointestinal illnesses. Our own studies have focused instead on the combination of GLP-1 receptor agonists (GLP-1RAs) with neuropeptide Y1- and Y2-receptor (Y1...